Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

SK bioscience will make strategic equity investment into Novavax to respond to the endemic and strengthen strategic partnership. SK bioscience and Novavax also extended their existing license agreement for Novavax's updated COVID vaccine.

SK bioscience Announces Equity Investment in Novavax to Strengthen Strategic Partnership

Novavax, Inc. (NASDAQ:NVAX ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Erika Schultz - Senior Director, IR John Jacob - President and CEO Filip Dubovsky - CMO John Trizzino - CCO and CBO James Kelly - CFO Conference Call Participants Roger Song - Jefferies Eric Joseph - JPMorgan Brendan Smith - TD Cowen Mayank Mamtani - B. Riley Alec Stranahan - Bank of America Vernon Bernardino - H.C.

Novavax, Inc. (NVAX) Q2 2023 Earnings Call Transcript

Although the revenue and EPS for Novavax (NVAX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Novavax (NVAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Novavax (NVAX) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of a loss of $1.24 per share. This compares to loss of $6.53 per share a year ago.

Novavax (NVAX) Q2 Earnings and Revenues Top Estimates

Novavax (NASDAQ: NVAX ) stock is climbing higher on Tuesday after the vaccine company released earnings results for the second quarter of the year. Included in that report is the company's diluted earnings per share of 58 cents.

Novavax (NVAX) Stock Gets a Boost From Q2 Vaccine Sales

Novavax is working to strengthen its financial position after it raised doubts about its ability to stay in business earlier this year.

Novavax shares jump after Covid vaccine maker posts surprise quarterly profit

Second quarter total revenue of $424 million and net income of $58 million Executed new strategic partnering agreement with SK bioscience, including an equity investment of $85 million in Novavax at $13.00 per share, a 59% premium to the 90-day VWAP Negotiated up to $350 million in 2023 payments under amended Canada APA Initiated FDA submission for approval of our updated XBB COVID vaccine for the 2023 fall vaccination season and reiterated plan to be in market by September; submissions to EMA and Health Canada in the coming weeks Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.

Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights

Novavax on Tuesday posted an unexpected second-quarter profit on earlier-than-expected revenue from its COVID-19 vaccine, but still trimmed its full-year forecast for sales of the shot.

Novavax posts unexpected Q2 profit on earlier COVID revenue

Novavax stock is on the rise after announcing a cost-cutting plan and bullish sales guidance. Is NVAX stock a buy or a sell today?

Is Novavax Stock A Buy Or A Sell As Shares Stage A Comeback On A Cost-Cutting Plan?

Arcturus Therapeutics

Axsome Therapeutics

Emergent BioSolutions

Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.

4 Biotech Stocks Set to Outpace Q2 Earnings Estimates

GAITHERSBURG, Md. , Aug. 1, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its second quarter 2023 financial results and operational highlights at 8:30 a.m.

Novavax to Host Conference Call to Discuss Second Quarter 2023 Financial Results and Operational Highlights on August 8, 2023

Bionano Genomics

ImmunityBio

American drug makers can generate gigantic profits, pushing their stock prices to great heights. The pharmaceutical sector is lucrative in general around the globe, while the space is very profitable in America in particular.

Looking for a Bargain? 3 Biotech Stocks to Buy That Are Down 20%-60% in 2023

The latest COVID-19 surge is encouraging some investors to load up on vaccine makers. The biotech's Nuvaxovid is one of three jabs authorized in the U.S. to tackle the disease.

Why Novavax Stock Zoomed 13% Higher on Monday

Moderna

Pfizer

Pfizer, Moderna and Novavax are slated to deliver new single-strain Covid shots targeting the omicron subvariant XBB.1.5 in September.

New Covid vaccines are coming to the U.S. this fall, but uptake may be low — Here's why

Novavax will see an influx of cash from Canada due to canceled COVID vaccines. The business' core fundamentals remain shaky, however, and that may not change.

2 Concerning Numbers Novavax Investors Shouldn't Ignore

Novavax invested heavily in the development of COVID-19 vaccines that are now less in demand. This year's top line is projected to shrink 31%.

Why Novavax Stock Tumbled 28% in the First Half of 2023

Novavax (NVAX) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Fast-paced Momentum Stock Novavax (NVAX) Is Still Trading at a Bargain

Amyris

MannKind

Ocugen, Inc.

Cassava Sciences Inc

VBI Vaccines

Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category.

7 Biotech Stocks to Sell in July

Novavax has struggled since it fell behind in the coronavirus vaccine race. An amendment to its deal with Canada is set to bring in $350 million this year.

Is This a Good Sign for Novavax?

Novavax (NVAX) is set to receive $350M from the Canadian government for forfeited Covid-19 vaccine doses per an amendment to the original purchase agreement between the parties. The stock rises 30%.

Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30%

Shares of Novavax soared over 29% after the Canadian government agreed to pay the biotech firm almost $350 million for canceling delivery of some COVID-19 vaccines previously ordered.

Novavax Shares Gain Over 29% After $350 Million Vaccine Deal With Canada

Embattled biotechnology firm Novavax (NASDAQ: NVAX ) — which previously incurred serious business viability risks — received much-needed positive news. On Friday after market close, the Canadian government announced that it will pay $349.6 million to settle a dispute surrounding its forfeiture of certain doses of Novavax's Covid-19 vaccine previously scheduled for delivery.

Why Is Novavax (NVAX) Up 30% Today?

Novavax shares moved higher after the vaccine maker announced that it would be paid $349.6 million from Canada for an unspecified quantity of forfeited COVID-19 vaccines previously set for delivery. Canada will pay the Maryland-based company in two equal installments in 2023, Novavax said in a Securities and Exchange Commission (SEC) filing.

Novavax to be paid $350M from Canada for unused COVID-19 vaccines; shares rise

Novavax's only commercial product line is COVID-19 vaccines. The company will receive payment from Canada for unused COVID-19 shots.

Why Shares of Novavax Are Up Monday

In February, the company said there was 'substantial doubt' about its ability to continue operating through this year.

News for Novavax Stock (NVAX)